Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-20
2007-02-20
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S286000
Reexamination Certificate
active
10629858
ABSTRACT:
The present invention relates to the albumin-guided development of coumarin analogs and the analogs developed thereby. The coumarin analogs of the present invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a minimum of metabolic complications and undesirable side effects.
REFERENCES:
patent: 2427578 (1947-09-01), Stahmann et al.
Roush et al, J. Org. Chem., vol. 52, p. 5127-5136 (1987).
Ivanov et al, Arch. Pharm. (Weinheim), vol. 323, p. 521-522 (1990).
Manolov et al, Eur. J. Med. Chem., vol. 30, p. 531-535 (1995).
Dentz Bernard
New Century Pharmaceuticals Inc.
Schulman B. Aaron
Stites & Harbison PLLC
LandOfFree
Coumarin analog compounds for safer anticoagulant treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Coumarin analog compounds for safer anticoagulant treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coumarin analog compounds for safer anticoagulant treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834459